Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AGL
stocks logo

AGL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.50B
-1.71%
-0.081
-67.75%
1.77B
+15.7%
0.056
-768.42%
1.81B
+29.59%
0.019
-107.46%
Estimates Revision
The market is revising Upward the revenue expectations for agilon health, inc. (AGL) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -39.33%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+19.33%
In Past 3 Month
Stock Price
Go Down
down Image
-39.33%
In Past 3 Month
Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 1.15 USD with a low forecast of 0.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 1.15 USD with a low forecast of 0.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
7 Hold
2 Sell
Hold
Current: 0.728
sliders
Low
0.50
Averages
1.15
High
1.50
Current: 0.728
sliders
Low
0.50
Averages
1.15
High
1.50
RBC Capital
Sector Perform -> Outperform
upgrade
$10 -> $11
2025-12-03
New
Reason
RBC Capital
Price Target
$10 -> $11
2025-12-03
New
upgrade
Sector Perform -> Outperform
Reason
RBC Capital upgraded AGL Energy to Outperform from Sector Perform with a price target of A$11, up from A$10. The firm cites the company's growing battery fleet and retail tariff tailwinds for the upgrade.
Evercore ISI
Elizabeth Anderson
In Line
downgrade
$1
2025-11-05
Reason
Evercore ISI
Elizabeth Anderson
Price Target
$1
2025-11-05
downgrade
In Line
Reason
Evercore ISI analyst Elizabeth Anderson lowered the firm's price target on Agilon Health to 50c from $1 and keeps an In Line rating on the shares. Q3 results were weaker than anticipated and the reinstated 2025 guidance suggests a challenging Q4 ahead, the analyst tells investors.
Bernstein
Lance Wilkes
Outperform -> Market Perform
downgrade
$4
2025-08-20
Reason
Bernstein
Lance Wilkes
Price Target
$4
2025-08-20
downgrade
Outperform -> Market Perform
Reason
Bernstein analyst Lance Wilkes downgraded Agilon Health to Market Perform from Outperform with a price target of $1.40, down from $4. The firm cites the company's worse than expected margin pressure for the downgrade. Agilon's margin challenges reduce its capital cushion and increases its cost of capital, which creates an uncertain growth outlook, the analyst tells investors in a research note. Bernstein does not see the company as representing a strategically valuable asset that could be attractive to buyers.
Jefferies
Jack Slevin
Hold
downgrade
2025-08-15
Reason
Jefferies
Jack Slevin
Price Target
2025-08-15
downgrade
Hold
Reason
Jefferies analyst Jack Slevin lowered the firm's price target on Agilon Health to $1.10 from $2.40 and keeps a Hold rating on the shares. The firm says Q2 showed that while efforts to address PYD and fundamental headwinds have been well-placed, Agilon Health is still facing challenges. The leadership shake-up leads Jefferies to belief that urgency is heightened to address these issues; the current cash balance leaves some runway to sort things out, but the firm thinks fairly aggressive options related to the portfolio could be on the table exiting FY25 based on MCO bids and current performance.
Baird
Neutral
downgrade
$5 -> $1
2025-08-14
Reason
Baird
Price Target
$5 -> $1
2025-08-14
downgrade
Neutral
Reason
Baird lowered the firm's price target on Agilon Health to $1 from $5 and keeps a Neutral rating on the shares. The firm adjusted the price target after updating its power rankings in managed care and healthcare facilities.
TD Cowen
Hold
downgrade
$4 -> $1
2025-08-06
Reason
TD Cowen
Price Target
$4 -> $1
2025-08-06
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Agilon Health to $1 from $4 and keeps a Hold rating on the shares. The firm noted they pre-announced a material revenue/medical margin/adj EBITDA miss primarily due to RAF revisions and unfavorable PYD. The company withdrew its 2025 guidance and announced its CEO stepped down and is searching for a replacement.
See All Ratings

Valuation Metrics

The current forward P/E ratio for agilon health inc (AGL.N) is -1.39, compared to its 5-year average forward P/E of -27.35. For a more detailed relative valuation and DCF analysis to assess agilon health inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.35
Current PE
-1.39
Overvalued PE
261.31
Undervalued PE
-316.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
105.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
602.45
Undervalued EV/EBITDA
-390.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.94
Current PS
0.00
Overvalued PS
3.95
Undervalued PS
-0.07
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 672.59% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 1326.49% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 672.59% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AGL News & Events

Events Timeline

(ET)
2025-11-07
07:24:17
Agilon Health Notified of Noncompliance by NYSE
select
2025-11-04 (ET)
2025-11-04
16:25:12
Agilon Health projects FY26 revenue between $5.81B and $5.83B, in line with consensus of $5.80B
select
2025-11-04
16:23:39
Agilon Health announces Q3 earnings per share of 27 cents, surpassing consensus estimate of 14 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-04Globenewswire
Agilon Health Faces Class Action for Misleading Business Information
  • Potential Litigation Investigation: Rosen Law Firm is investigating potential securities claims against Agilon Health (NYSE: AGL) for allegedly issuing materially misleading business information, indicating that investors may face significant losses.
  • Stock Price Plunge: Following Agilon Health's Q2 2025 results announcement on August 4, which highlighted more acute industry headwinds than expected, the stock plummeted 51.5% the next day, reflecting strong market concerns about the company's outlook.
  • Suspension of Financial Guidance: The company announced the suspension of its previously issued full-year 2025 financial guidance and related assumptions, indicating major challenges in an uncertain market environment that could undermine future investor confidence.
  • Legal Action Opportunity: Investors can join the class action through Rosen Law Firm without any out-of-pocket fees, demonstrating the firm's commitment to providing legal support for investors facing potential losses.
[object Object]
Preview
7.0
12-04Globenewswire
Agilon Health CEO Resignation Triggers 27% Stock Drop
  • Leadership Transition: On August 4, 2025, Agilon Health, Inc. announced the resignation of CEO Steven Sell, resulting in a more than 27% drop in the company's stock price during after-hours trading, indicating strong market reactions to leadership instability.
  • Guidance Withdrawal: The company also withdrew its full-year 2025 earnings guidance, which surprised the market and exacerbated investor anxiety, potentially impacting future financing capabilities and market confidence.
  • Legal Investigation Initiated: Bragar Eagel & Squire, P.C. is investigating whether Agilon failed to disclose material information related to the leadership transition, which could violate federal securities laws; unfavorable findings could have long-term repercussions on the company's reputation and stock price.
  • Market Reaction: The stock price of Agilon was severely impacted by the leadership changes and guidance withdrawal, leading to investor concerns about the company's future profitability and stability, which may result in further capital outflows.
[object Object]
Preview
7.0
12-03PRnewswire
Rosen Law Firm Investigates Securities Claims Against Agilon Health (AGL) Following 51.5% Stock Drop
  • Securities Fraud Investigation: The Rosen Law Firm is investigating potential securities claims against Agilon Health for possibly issuing materially misleading business information, indicating a strong commitment to protecting investor rights.
  • Stock Price Plunge: Following Agilon Health's announcement on August 4, 2025, to suspend its full-year 2025 financial guidance, the stock plummeted by 51.5% the next day, reflecting significant market concerns about the company's outlook.
  • Legal Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, demonstrating the firm's dedication to advocating for shareholder rights in the face of corporate misconduct.
  • Increased Industry Challenges: Agilon Health's Executive Chair noted that industry headwinds are more acute than previously expected, suggesting that external pressures could adversely affect the company's future financial performance and market confidence.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is agilon health inc (AGL) stock price today?

The current price of AGL is 0.728 USD — it has increased 7.21 % in the last trading day.

arrow icon

What is agilon health inc (AGL)'s business?

agilon health, inc. is a healthcare company. It enables primary care physicians (PCP) to be the agents for change in the communities they serve. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of its physician partners’ attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform is holistic in supporting the rapid transition to a Total Care Model with technology, people, process and capital.

arrow icon

What is the price predicton of AGL Stock?

Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 1.15 USD with a low forecast of 0.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is agilon health inc (AGL)'s revenue for the last quarter?

agilon health inc revenue for the last quarter amounts to 1.44B USD, decreased -1.08 % YoY.

arrow icon

What is agilon health inc (AGL)'s earnings per share (EPS) for the last quarter?

agilon health inc. EPS for the last quarter amounts to -0.27 USD, decreased -6.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for agilon health inc (AGL)'s fundamentals?

The market is revising Upward the revenue expectations for agilon health, inc. (AGL) for FY2025, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by -39.33%.
arrow icon

How many employees does agilon health inc (AGL). have?

agilon health inc (AGL) has 1076 emplpoyees as of December 05 2025.

arrow icon

What is agilon health inc (AGL) market cap?

Today AGL has the market capitalization of 302.31M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free